Evidence map›Paper›PMID 31849645›Full record

ArticleFrontiers in pharmacology2019

Recalcitrant Issues and New Frontiers in Nano-Pharmacology.

Vinay Bhardwaj, Ajeet Kaushik, Ziad M Khatib, Madhavan Nair, Anthony J McGoron

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Nanomedicines against Chagas disease: a critical review.Beilstein journal of nanotechnology · 2024
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Vinay BhardwajDepartment of Biomedical Engineering, The College of New Jersey, Ewing, NJ, United States.
Ajeet KaushikDepartment of Natural Sciences, Florida Polytechnic University, Lakeland, FL, United States.
Ziad M KhatibDivision of Hematology Oncology, Department of Pediatrics, Nicklaus Children's Hospital, Miami, FL, United States.
Madhavan NairCenter for Personalized Nanomedicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States.
Anthony J McGoronDepartment of Biomedical Engineering, Florida International University, Miami, FL, United States.
Florida International University · USCollege of New Jersey · USFlorida Polytechnic University · USMiami Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Packaging of old pharma drugs into new packaging "nanoparticles" is called nano-pharmacology and the products are called nano-based drugs. The inception of nano-pharmacology research and development (R&D) is marked by the approval of the first nano-based drug Doxil

Indexed as

Doxilnano-based drugsnanomedicinenanoparticlesresearch and developmenttheranostics

Identifiers

PMID31849645
PMCPMC6897283
OpenAlexW2983937454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.